Sigachi Industries makes microcrystalline cellulose (MCC), the most widely used pharmaceutical excipient, and also produces active pharmaceutical ingredients and operates an operations and maintenance services vertical. Its manufacturing sites at Dahej and Jhagadia supply formulation makers in more than 60 countries, with exports contributing about 65% of FY26 turnover. In Q4 FY26, total operating income was INR 121.89 crores, of which MCC contributed INR 85.33 crores or roughly 70%, API INR 17.06 crores, and O&M INR 14.63 crores. The competitive structure is favorable: Chinese MCC producers are not meaningful competitors in regulated markets because customers qualify suppliers slowly, and Sigachi has built repeat business of 80-90% over roughly three decades. Margins are temporarily depressed by the Hyderabad facility shutdown, with Q4 FY26 EBITDA at 12.63%, but the pre-incident MCC business operated above 20% and O&M is running at 21-22%. That combination of niche share and structurally high margins defines where the money is made.
The persistence of these economics rests on switching costs and qualification cycles, not on commodity scale. MCC is a small fraction of a tablet's total cost, yet it is mixed with high-value APIs, so a formulation maker will not change suppliers lightly. Customers who moved to alternate vendors during the supply disruption are expected to return as preferred suppliers once production resumes, and management reports no pricing erosion; MCC realization rose from INR 212 per kg in H1 FY25 to INR 216 per kg in H1 FY26. The asset base is also hard to replicate: current cellulose capacity is 18,000 mtpa, and the company holds 20 acres at Dahej and 25 acres at Kurnool for expansion. Because approved supplier status and product registrations take years to obtain, capacity added by new entrants does not quickly convert to competitive threat. This is a converter business where the barrier is customer approval, not just capital.
The inflection is the commissioning of two projects. The 12,000 mtpa MCC expansion at Dahej, with capex of INR 106 crores, is guided for COD by Q4 FY27 and will lift total cellulose-based excipient capacity to 30,000 mtpa. The 1,800-ton CCS disintegrant facility at Dahej SEZ, capex INR 90 crores, is guided for commercialization in Q1 FY28. Current utilization was only 75-80% as of March 31, 2026, but management expects it to climb to 95-97% as safety audits normalize, with the new line ramping from about 30% in Q1 FY27 to 40-50% in Q2 and gradually higher. FY27 revenue is guided at INR 650-675 crores with 18-20% EBITDA margins. By 18-24 months out, the new MCC line should be contributing INR 200-220 crores of revenue, CCS around INR 100 crores at above 20% EBITDA margins, and API revenue should exceed INR 100 crores in FY27. That puts the business on a path toward roughly INR 1,000 crores of revenue by FY29.
Management's track record on timelines has slipped by one quarter. The October 2025 call targeted FY26 revenue of at least INR 575 crores and Q3 FY27 commissioning for both expansions; the February 2026 call reiterated Q3 FY27 and expected an ad hoc insurance payment by March 31, 2026. The June 2026 call moved MCC commissioning to Q4 FY27, CCS to Q1 FY28, and put the ad hoc insurance amount of INR 20-25 crores at June 25-30, 2026, while setting the FY27 revenue guidance of INR 650-675 crores. The FY26 revenue target appears to have been overtaken by the disruption, and the company now emphasizes a multi-quarter recovery. Capital allocation is conservative in one sense: there is no long-term debt, only working capital borrowings. But the combined INR 196 crores of capex is not yet fully funded, and management discusses a mix of internal accruals, debt, and possible equity. The credit rating was downgraded after the incident, and promoters intend to gradually increase their stake.
The earnings path is quantified: FY27 revenue of INR 650-675 crores at an 18-20% EBITDA margin implies EBITDA of roughly INR 117-135 crores, against Q4 FY26 EBITDA of INR 15.4 crores and materially weaker earlier quarters. To get there, utilization must reach 90%+ in FY27, the Dahej line must hit COD by Q4 FY27, and customers who shifted to other vendors must return. The single most important falsifier is the Dahej commissioning date; a slip beyond Q4 FY27 would push revenue into FY28 and likely force a cut to the 650-675 crores guide. The secondary watchpoint is the Hyderabad litigation, with court clarity expected in about six months, because a restart would add capacity and insurance proceeds of about INR 70 crores would strengthen the balance sheet. The tension between depressed current PAT and guided margin expansion is operational, not structural: it reflects one-time shutdown and transition costs, fixed overhead absorption, and a better CCS/API mix, all of which depend on execution.
companyname: Sigachi Industries Limited ticker: SIGACHI sector: Pharmaceutical Excipients / Specialty Chemicals Sigachi was founded in 1989 in Hyderabad and has spent 36 years building one of the world's largest microcrystalline cellulose (MCC) businesses. The annual report places it among the top 5 MCC manufacturers globally, with roughly 22,000 MTPA of MCC capacity across three plants. MCC is the most common excipient in pharmaceutical tablets - the inert ingredient that binds, disintegrates,...
Read the full report →capex, margin expansion
FY27 revenue guided at INR 650-675 crores with EBITDA margin of 18-20% driven by incremental capacities from Dahej and Jhagadia and improved product mix
Guidance upgradedGet valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Sigachi Industries Limited and 4,900+ companies.
5-day free pass. No card required.